111 (NASDAQ:YI – Get Free Report) and Precipio (NASDAQ:PRPO – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.
Insider and Institutional Ownership
21.3% of 111 shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 43.9% of 111 shares are owned by insiders. Comparatively, 16.6% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares 111 and Precipio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| 111 | $1.80 billion | 0.03 | -$9.65 million | ($1.00) | -5.78 |
| Precipio | $24.05 million | 1.84 | -$360,000.00 | ($0.47) | -52.51 |
Precipio has lower revenue, but higher earnings than 111. Precipio is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
111 has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Precipio has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Profitability
This table compares 111 and Precipio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 111 | -0.53% | N/A | -2.72% |
| Precipio | -3.57% | -6.73% | -4.49% |
Analyst Ratings
This is a summary of recent ratings for 111 and Precipio, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 111 | 1 | 0 | 0 | 0 | 1.00 |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
Summary
111 beats Precipio on 7 of the 11 factors compared between the two stocks.
About 111
111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
